Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

(PPHM, MJGCF, OSN, GBLHF, ATRM) Stock in Focus by

Stock-PR Reporting



FREE Daily Stock Alerts From




Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, announced the completion of enrollment and randomization of 121 patients in a double-blind, placebo-controlled Phase II trial evaluating bavituximab in combination with docetaxel in patients with previously treated locally advanced or metastatic non-small cell lung cancer (NSCLC). Bavituximab is a phosphatidylserine (PS)-targeting monoclonal antibody with broad therapeutic potential also being evaluated in randomized Phase II trials for front-line NSCLC, pancreatic cancer, and hepatitis C virus (HCV) infection as well as in several investigator-sponsored trials (ISTs) in additional oncology indications.

Read full article and disclaimer at :